Literature DB >> 10936422

Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

H G Drexler1, Y Matsuo.   

Abstract

Multiple myeloma (MM) is a neoplasm of a terminally differentiated B-cell. The disease is progressive and always lethal characterized by the slow proliferation of malignant plasma cells in the bone marrow. Much of our current understanding of the biology of MM has been obtained by studying MM-derived cell lines. Human myeloma cell lines were shown to be suitable model systems for use in various fields of the biological sciences. However, it has proved very difficult to establish cell lines from plasma cell dyscrasias. Most reported MM cell lines have been derived from patients with advanced disease and from extramedullary sites. Nevertheless, within the last 20 years more than 100 cell lines have been established. A significant portion of this panel is partially or well characterized with regard to their cell culture, clinical, immunophenotypic, cytogenetic and functional features. Distinct immunoprofiles could be assigned to MM cell lines. All MM cell lines display chromosomal aberrations; in more than 80% of the cell lines analyzed, chromosome 14 band q32 (immunoglobulin heavy chain locus) is affected; the various types of 14q+ chromosomes showed different distributions among the MM cell lines. A large percentage of MM cell lines is constitutively interleukin-6-dependent or responsive to various cytokines. It is important to realize that not every cell line established from a patient with myeloma is a neoplastic cell line. So-called 'myeloma cell lines' have been previously reported and are still widely used which are in reality Epstein-Barr virus (EBV)-positive B-lymphoblastoid cell lines. The presence of the EBV-genome in residual normal B-cells provides them with a selective growth advantage after explantation. In summary, a significant number of authentic and well-characterized MM cell lines has been established and described. The availability of these bona fide MM cell lines is of great importance for the study of the biology, etiology and treatment of the disease.

Entities:  

Mesh:

Year:  2000        PMID: 10936422     DOI: 10.1016/s0145-2126(99)00195-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  25 in total

Review 1.  Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

2.  Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

Authors:  Esther A Obeng; Louise M Carlson; Delia M Gutman; William J Harrington; Kelvin P Lee; Lawrence H Boise
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

3.  Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation.

Authors:  Brian A Keller; Brian J Laight; Oliver Varette; Aron Broom; Marie-Ève Wedge; Benjamin McSweeney; Catia Cemeus; Julia Petryk; Bryan Lo; Bruce Burns; Carolyn Nessim; Michael Ong; Roberto A Chica; Harold L Atkins; Jean-Simon Diallo; Carolina S Ilkow; John C Bell
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-08       Impact factor: 4.553

4.  Use of transcriptional signatures induced in lymphoid and myeloid cell lines as an inflammatory biomarker in Type 1 diabetes.

Authors:  Shuang Jia; Mary Kaldunski; Parthav Jailwala; Rhonda Geoffrey; Joanna Kramer; Xujing Wang; Martin J Hessner
Journal:  Physiol Genomics       Date:  2011-03-15       Impact factor: 3.107

5.  IgA Monoclonal Gammopathy with Pseudohyperphosphatemia.

Authors:  Priti Rani; Tarun Kumar; Sushil Kumar; Ayan Banerjee; Mala Mahto
Journal:  Indian J Clin Biochem       Date:  2020-07-06

Review 6.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

Review 7.  Persistent use of false myeloma cell lines.

Authors:  Hans G Drexler; Yoshinobu Matsuo; Roderick A E MacLeod
Journal:  Hum Cell       Date:  2003-09       Impact factor: 4.174

8.  OH-2, a hyperdiploid myeloma cell line without an IGH translocation, has a complex translocation juxtaposing MYC near MAFB and the IGK locus.

Authors:  Thea Kristin Våtsveen; Erming Tian; Stine H Kresse; Leonardo A Meza-Zepeda; Ana Gabrea; Oleg Glebov; Hong Yan Dai; Anders Sundan; W Michael Kuehl; Magne Børset
Journal:  Leuk Res       Date:  2009-04-23       Impact factor: 3.156

9.  Characterization of MYC translocations in multiple myeloma cell lines.

Authors:  Amel Dib; Ana Gabrea; Oleg K Glebov; P Leif Bergsagel; W Michael Kuehl
Journal:  J Natl Cancer Inst Monogr       Date:  2008

10.  A comparison between protein profiles of B cell subpopulations and mantle cell lymphoma cells.

Authors:  Henrik Stranneheim; Lukas M Orre; Janne Lehtiö; Jenny Flygare
Journal:  Proteome Sci       Date:  2009-11-23       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.